Thu 25 Jun 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
| Product | Date | Safety information | Attachments |
|---|---|---|---|
| Gilenya® - Fingolimod | Hemophagocytic syndrome (HPS) reported in patients treated with Gilenya®. |
||
| Neupogen® - Filgrastim | Risk of capillary leak syndrome in patients with cancer. |
||
| ZOFRAN® - Ondansetron | Updated information on posology for intravenous use and dose dependant QT interval prolongation. |
||
| Diane-35® - Ethinylestradiol/Cyproterne | Risk of Thromboembolism. |
||
| MabThera® - Rituximab | The management of hepatitis B reactivation in patients treated with MabThera®. CLICK HERE |
||
| LARIAM® - Mefloquine | Important Safety Update of Prescribing Information for LARIAM®. |
||
| Fenatnyl‐Janssen ® - Fentanyl | Fenatnyl‐Janssen Introduction of New Warning ‐ Serontonin syndrome may occur under co‐administration with serotonergic drugs. |
||
| DUROGESIC® -Fentanyl | Introduction of New Warning-Serontonin syndrome may occur under co-administration with serotonergic drugs. |
||
| VOTRIENT® - Pazopanib | Important change to frequency of Serum liver test monitoring for hepatotoxicity. |
||
| TASIGNA® - Nilotinib | Updated information regarding the possible risk of developing atherosclerosis-related diseases with the use of TASIGNA®. |
Last update date: 21/04/2024 at 10:00 AM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.